Atea Pharmaceuticals Inc (NASDAQ: AVIR) has experienced a decline in its stock price by -0.60 compared to its previous closing price of 3.36. However, the company has seen a fall of -0.30% in its stock price over the last five trading days. globenewswire.com reported 2025-01-08 that BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 5:15 p.m. PT in San Francisco, CA.
Is It Worth Investing in Atea Pharmaceuticals Inc (NASDAQ: AVIR) Right Now?
Company’s 36-month beta value is 0.19.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for AVIR is 74.01M, and currently, short sellers hold a 4.30% ratio of that floaft. The average trading volume of AVIR on January 09, 2025 was 303.72K shares.
AVIR’s Market Performance
AVIR’s stock has seen a -0.30% decrease for the week, with a 13.61% rise in the past month and a -2.05% fall in the past quarter. The volatility ratio for the week is 4.29%, and the volatility levels for the past 30 days are at 4.51% for Atea Pharmaceuticals Inc The simple moving average for the past 20 days is 3.81% for AVIR’s stock, with a -6.22% simple moving average for the past 200 days.
Analysts’ Opinion of AVIR
Many brokerage firms have already submitted their reports for AVIR stocks, with Morgan Stanley repeating the rating for AVIR by listing it as a “Equal-Weight.” The predicted price for AVIR in the upcoming period, according to Morgan Stanley is $6.88 based on the research report published on August 13, 2024 of the previous year 2024.
Morgan Stanley gave a rating of “Underweight” to AVIR, setting the target price at $7 in the report published on January 06th of the previous year.
AVIR Trading at 2.19% from the 50-Day Moving Average
After a stumble in the market that brought AVIR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.39% of loss for the given period.
Volatility was left at 4.51%, however, over the last 30 days, the volatility rate increased by 4.29%, as shares surge +10.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.30% lower at present.
During the last 5 trading sessions, AVIR fell by -0.30%, which changed the moving average for the period of 200-days by -17.73% in comparison to the 20-day moving average, which settled at $3.22. In addition, Atea Pharmaceuticals Inc saw -0.30% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AVIR starting from BERGER FRANKLIN M, who sale 359,606 shares at the price of $2.85 back on Dec 10 ’24. After this action, BERGER FRANKLIN M now owns 451,897 shares of Atea Pharmaceuticals Inc, valued at $1,023,475 using the latest closing price.
Franklin Berger, the Lead Independent Director of Atea Pharmaceuticals Inc, proposed sale 359,606 shares at $2.85 during a trade that took place back on Dec 10 ’24, which means that Franklin Berger is holding shares at $1,023,475 based on the most recent closing price.
Stock Fundamentals for AVIR
The total capital return value is set at -0.43. Equity return is now at value -33.45, with -31.67 for asset returns.
Currently, EBITDA for the company is -119.59 million with net debt to EBITDA at 0.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.33.
Conclusion
In a nutshell, Atea Pharmaceuticals Inc (AVIR) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
